IP Library Granted Patent US 7,732,546
Granted Patent B2
US 7,732,546 · App. 12/203,309 · Granted Jun 8, 2010

Use of silylated sulfonate monomers to improve contact lens wettability

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,732,546
App. No.
12/203,309
Granted
Jun 8, 2010
Kind
B2
Abstract

The present invention relates to polymeric compositions useful in the manufacture of biocompatible medical devices. More particularly, the present invention relates to certain hydrophilic monomers capable of polymerization to form polymeric compositions having desirable physical characteristics useful in the manufacture of ophthalmic devices. The polymeric compositions comprise polymerizable hydrophilic siloxanyl monomers.

Claims (22)

1. A monomer mix comprising a monomer of Formula (I):

V-L-A-Si(R) 3   Formula (I)

and a second monomer Formula (II):

V-L-N(R) 2   Formula (II)

wherein V is a polymerizable ethylenically unsaturated organic radical, L is divalent linking group; A is a residue capable of forming organic acids, salts or esters selected from the group consisting of sulfonates, sulfates, sulfites, phosphates, phosphites, pyrophosphates and phosphonates; and R is independently a monovalent radical.

2. The monomer mix of claim 1 wherein L is selected from the group consisting of a bond, a straight or branched C1-C30 alkyl radical, a C1-C30 fluoroalkyl radical, a C1-C20 ester-containing radical, an alkyl ether radical, cycloalkyl ether radical, cycloalkenyl ether radical, aryl ether radical, arylalkyl ether radical, a polyether containing radical, a substituted or unsubstituted C1-C30 alkoxy radical, a substituted or unsubstituted C3-C30 cycloalkyl radical, a substituted or unsubstituted C3-C30 cycloalkylalkyl radical, a substituted or unsubstituted C3-C30 cycloalkenyl radical, a substituted or unsubstituted C5-C30 aryl radical, a substituted or unsubstituted C5-C30 arylalkyl radical, a substituted or unsubstituted C5-C30 heteroaryl radical, a substituted or unsubstituted C3-C30 heterocyclic ring, a substituted or unsubstituted C4-C30 heterocyclolalkyl radical, a substituted or unsubstituted C6-C30 heteroarylalkyl radical, a C5-C30 fluoroaryl radical, or a hydroxyl substituted alkyl ether and combinations thereof.

3. The monomer mix of claim 1 wherein R is selected from the group consisting of hydrogen, a straight or branched C1-C30 alkyl radical, a C1-C30 fluoroalkyl radical, a C1-C20 ester-containing radical, an alkyl ether radical, cycloalkyl ether radical, cycloalkenyl ether radical, aryl ether radical, arylalkyl ether radical, a polyether containing radical, a substituted or unsubstituted C1-C30 alkoxy radical, a substituted or unsubstituted C3-C30 cycloalkyl radical, a substituted or unsubstituted C3-C30 cycloalkylalkyl radical, a substituted or unsubstituted C3-C30 cycloalkenyl radical, a substituted or unsubstituted C5-C30 aryl radical, a substituted or unsubstituted C5-C30 arylalkyl radical, a substituted or unsubstituted C5-C30 heteroaryl radical, a substituted or unsubstituted C3-C30 heterocyclic ring, a substituted or unsubstituted C4-C30 heterocyclolalkyl radical, a substituted or unsubstituted C6-C30 heteroarylalkyl radical, fluorine, a C5-C30 fluoroaryl radical.

4. The monomer mix of claim 1 , further comprising a hydrophobic monomer and a hydrophilic monomer.

5. The monomer mix of claim 4 wherein the hydrophilic monomer is selected from the group consisting of unsaturated carboxylic acids; methacrylic acids, acrylic acids; itaconic acid; itaconic acid esters; acrylic substituted alcohols; 2-hydroxyethyl methacrylate, 2-hydroxyethyl acrylate; vinyl lactams; N-vinylpyrrolidone; N-vinylcaprolactone; acrylamides; methacrylamide, N,N-dimethylacrylamide; methacrylates; ethylene glycol dimethacrylate, methyl methacrylate, allyl methacrylate; hydrophilic vinyl carbonates, hydrophilic vinyl carbamate monomers; hydrophilic oxazolone monomers, 3-methacryloxypropyltris(trimethylsiloxy)silane, ethylene glycol dimethacrylate, allyl methacrylate and mixtures thereof.

6. A biomedical device comprising a polymerized monomer mixture of claim 1 .

7. The monomer mix of claim 1 wherein the monomer of Formula (I) is selected from the group consisting of Formulae (III)-(VI) below:

8. A method of making a biomedical device comprising:

providing a monomer mixture comprising a monomer of Formula (I):

V-L-A-Si(R) 3   Formula (I)

and a second monomer of Formula (II):

V-L-N(R) 2   Formula (II)

wherein V is a polymerizable ethylenically unsaturated organic radical, L is divalent linking group; A is a residue capable of forming organic acids, salts or esters selected from the group consisting of sulfonates, sulfates, sulfites, phosphates, phosphites, pyrophosphates and phosphonates; and R is independently a monovalent radical;

subjecting the monomer mixture to polymerizing conditions to provide a polymerized device;

extracting the unpolymerized monomers from the polymerized device; and

packaging and sterilizing the polymerized device.

9. The method of claim 8 wherein the step of extracting is performed with non-flammable solvents.

10. The method of claim 8 wherein the step of extracting is performed with water.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Aug 5, 2010
From: BAUSCH & LOMB INCORPORATED
To: CREDIT SUISSE AG, AS ADMINISTRATIVE AGENT
Reel/Frame 024785/0948 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2008
From: SALAMONE, JOSEPH C.; KUNZLER, JAY F.
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 021474/0752 →